CN Patent

CN102482249B — 用于治疗皮肤病症或疾病状态的tofa类似物

Assigned to Dermira Canada Inc · Expires 2016-06-08 · 10y expired

What this patent protects

本发明涉及5-(十四烷基氧基)-2-呋喃羧酸(TOFA)的类似物及其在诸如痤疮和油性皮肤的以皮脂腺功能亢进为特征的皮肤病症或疾病状态及其它皮肤病症和疾病状态的治疗中的用途。本发明还涉及包含TOFA的类似物和用于皮肤给药或口服给药的药物可接受的赋形剂的药物组合物。通式(I)。

USPTO Abstract

本发明涉及5-(十四烷基氧基)-2-呋喃羧酸(TOFA)的类似物及其在诸如痤疮和油性皮肤的以皮脂腺功能亢进为特征的皮肤病症或疾病状态及其它皮肤病症和疾病状态的治疗中的用途。本发明还涉及包含TOFA的类似物和用于皮肤给药或口服给药的药物可接受的赋形剂的药物组合物。通式(I)。

Drugs covered by this patent

Patent Metadata

Patent number
CN102482249B
Jurisdiction
CN
Classification
—
Expires
2016-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Dermira Canada Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.